SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 130310.
  • 2
    Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 437.
  • 3
    Ribas A. Anti-CTLA4 antibody clinical trials in Melanoma. Update Cancer Ther 2007; 2: 13339.
  • 4
    Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007; 13: 523842.
  • 5
    Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297339.
  • 6
    Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 61118.
  • 7
    Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 45965.
  • 8
    Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 40513.
  • 9
    Greenwald RJ, Oosterwegel MA, Van Der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002; 32: 36673.
  • 10
    Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313: 19725.
  • 11
    Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 9858.
  • 12
    Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 5417.
  • 13
    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 17346.
  • 14
    Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 35566.
  • 15
    Van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001; 194: 4819.
  • 16
    Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 2005; 6: 58291.
  • 17
    Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100: 471217.
  • 18
    Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100: 837277.
  • 19
    Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 74150.
  • 20
    Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 604353.
  • 21
    Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175: 774654.
  • 22
    Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 100516.
  • 23
    Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005; 23: 896877.
  • 24
    Weber JS, Targan S, Scotland R, Snively J, Garcia M, Yellin M et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol 2006; 24: Abstract 2510.
  • 25
    Weber JS, Hersh EM, Yellin M, Nichol GM, Urba W, Powderly JD et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. J Clin Oncol 2007; 25: Abstract 8523.
  • 26
    Ribas A, Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J Clin Oncol 2007; 25: Abstract 3000.
  • 27
    Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall MA. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008; 26: Abstract LBA9011.
  • 28
    O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 261427.
  • 29
    Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006; 106: 243744.
  • 30
    Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 22839.
  • 31
    Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D et al. Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206. J Clin Oncol 2007; 25: Abstract 3038.
  • 32
    Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28: 5938.
  • 33
    Hodi FS, Hoos A, Ibrahim R, Chin K, Pehamberger H, Harmankaya K et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol 2008; 26: Abstract 3008.
  • 34
    Weber JS, Berman D, Siegel J, Minor D, Amin A, Thompson JA et al. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol 2008; 26: Abstract 9010.
  • 35
    O'Day SJ, Ibrahim R, DePril V, Maio M, Chiarion-Sileni V, Gajewski TF et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol 2008; 26: Abstract 9021.
  • 36
    Wolchok JD, Ibrahim R, DePril V, Maio M, Queirolo P, Harmankaya K et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. J Clin Oncol 2008; 26: Abstract 3020.
  • 37
    Hamid O, Chin K, Li J, Neyns B, Linette G, Negrier S et al. Dose effect of ipilimumab in patients with advanced melanoma: results from a phase II, randomized, dose-ranging study. J Clin Oncol 2008; 26: Abstract 9025.
  • 38
    Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105: 300510.